English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

3SBio Signs Exclusive License Agreement for an Antibody-Drug Conjugate Targeting HER2 with Alteogen

Oct. 12, 2015

3SBio announced that it has entered into an exclusive licensing deal with Korean Alteogen for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate ("ADC") targeting HER2 pathway for cancer in China, Hong Kong and Macau. The deal includes undisclosed upfront, milestone and royalty payments.

The preclinical proof-of-concept, including in-vitro binding assays and in-vivo efficacy in animal models, has demonstrated superiority of the ALT-P7 over current drugs in murine models of HER2-positive breast cancer.